Author:
Wang Lijin,Li Xiaokang,Li Tian,Liu Lin,Wang Haiyan,Wang Chiyao
Abstract
The incidence of coronary heart disease (CAD) has soared over the years, and coronary intervention has become an increasingly important therapeutic approach. The past decade has witnessed unprecedented developments in therapeutic medical instruments. Given that drug-coated balloons bring many benefits, they are indicated for an increasing number of conditions. In this article, we review the results of current clinical trials about drug-coated balloons and summarize their safety and clinical progression in different coronary artery diseases, laying the groundwork for basic research, and clinical therapeutics of this patient population.
Funder
Natural Science Foundation of Shaanxi Province
Subject
Cardiology and Cardiovascular Medicine
Reference129 articles.
1. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines;Lawton;Circulation,2022
2. Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990-2017: results from the global burden of disease study 2017;Dai;Eur Heart J Qual Care Clin Outcomes,2022
3. Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985-1986 PTCA and 1997-2006 dynamic registries;Venkitachalam;Circ Cardiovasc Interv,2009
4. Restenosis: delineating the numerous causes of drug-eluting stent restenosis;Farooq;Circ Cardiovasc Interv,2011
5. Drug eluting balloon for the treatment of patients with coronary artery disease: current perspectives;Lunardi;Cardiovasc Revasc Med,2018
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献